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1002Objective: Permanent biventricular pacing benefits patients with heart failure and interventricular conduction
delay, but the importance of pacing with and without optimization in patients at risk of low cardiac output after
cardiac surgery is unknown.We hypothesized that pacing parameters independently affect cardiac output. Accord-
ingly, we analyzed aortic flowmeasuredwith an electromagnetic flowmeter in patients at risk of low cardiac output
during an ongoing randomized clinical trial of biventricular pacing (n ¼ 11) versus standard of care (n ¼ 9).
Methods: A substudy was conducted in all 20 patients in both groups with stable pacing after coronary artery
bypass grafting, valve surgery, or both. Ejection fraction averaged 33%  15%, and QRS duration was
116 19 ms. Effects were measured within 1 hour of the conclusion of cardiopulmonary bypass. Atrioventricular
delay (7 settings) and interventricular delay (9 settings) were optimized in random sequence.
Results: Optimization of atrioventricular delay (171  8 ms) at an interventricular delay of 0 ms increased flow
by 14% versus the worst setting (111 11 ms, P<.001) and 7% versus nominal atrioventricular delay (120 ms,
P< .001). Interventricular delay optimization increased flow 10% versus the worst setting (P< .001) and 5%
versus nominal interventricular delay (0 ms, P< .001). Optimized pacing increased cardiac output 13% versus
atrial pacing at matched heart rate (5.5 0.5 vs 4.9 0.6 L/min, P¼ .003) and 10% versus sinus rhythm (5.0
0.6 L/min, P ¼ .019).
Conclusions: Temporary biventricular pacing increases intraoperative cardiac output in patients with left ventric-
ular dysfunction undergoing cardiac surgery. Atrioventricular and interventricular delay optimization maximizes
this benefit. (J Thorac Cardiovasc Surg 2011;141:1002-8)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular Surwith left ventricular (LV) dysfunction and intraventricular
conduction delay (IVCD).1 Permanent BiVP improves LV
dimension and function and decreases morbidity and mortal-
ity, although it is associated with a nonresponse rate of up to
30%.2-5 Although the long-term benefits of BiVP are typi-
cally not appreciated until several months after implantation,
hemodynamic effects of changes to pacing parameters are re-
flected acutely by metrics such as stroke volume, ventricular
dyssynchrony, and the maximal first derivative of pressure
(dP/dtmax).
6,7 These properties have facilitated the study of
the optimization of programmable BiVP parameters, such
as atrioventricular delay (AVD) and interventricular delay
(VVD), to maximize the hemodynamic benefit of BiVP
and to reduce its nonresponse rate.8-10
The acute hemodynamic effects of BiVP also enable the
study of temporary BiVP as a treatment for low output states
after cardiac surgery. Low left ventricular ejection fraction
(LVEF) is an independent risk factor for poor outcomes
after cardiac surgery.11 BiVP improves hemodynamics
without increasing myocardial oxygen consumption,7 and
therefore it is particularly appealing as a potential therapy
in patients undergoing cardiac surgery. Prior studies have
assessed temporary perioperative BiVP in heterogeneous
groups of patients with varying results.12-24 Moreover, thegery c April 2011
Abbreviations and Acronyms
AAI ¼ atrial pacing
AVD ¼ atrioventricular delay
BiPACS ¼ BiVP After Cardiac Surgery
BiVP ¼ biventricular pacing
CABG ¼ coronary artery bypass grafting
CHF ¼ congestive heart failure
CO ¼ cardiac output
CPB ¼ cardiopulmonary bypass
dP/dtmax ¼ maximal first derivative of pressure
IVCD ¼ intraventricular conduction delay
LV ¼ left ventricle
LVEF ¼ left ventricular ejection fraction
NSR ¼ sinus rhythm with no pacing
RA ¼ right atrium
RV ¼ right ventricle
VVD ¼ interventricular delay
Wang et al Perioperative Management
P
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perioperative setting is unclear.25,26
The BiVP After Cardiac Surgery (BiPACS) trial is a ran-
domized clinical trial to study the effect of optimized tempo-
rary BiVP on cardiac output (CO) in postoperative cardiac
surgery patients with preoperative LV systolic dysfunction
and an IVCD. Patients undergo BiVP optimization at multi-
ple time points in the intraoperative and postoperative pe-
riods and are randomized to continuous optimized BiVP
versus standard of care. The hypothesis underlying the Bi-
PACS trial is that CO will increase 15% in patients under-
going temporary BiVP. In this substudy of the BiPACS
trial, we hypothesized that optimization of pacing parame-
ters would increase CO. Accordingly, we assessed the con-
tribution of AVD and VVD optimization to the effect of
BiVP optimization in the intraoperative period after separa-
tion from cardiopulmonary bypass (CPB) and evaluated the
effect of optimized BiVP on CO compared with atrial pacing
(AAI) and with sinus rhythm with no pacing (NSR).MATERIALS AND METHODS
BiPACS Trial Study Population
The study protocol was approved by the Columbia University Medical
Center Institutional Review Board. Adult patients undergoing elective car-
diac surgery on CPB were screened for eligibility to enroll in the BiPACS
trial. All patients provided written informed consent. Recruitment was
done before the day of the operation by qualified and trained study coordi-
nators and investigators on the study team with permission of the attending
surgeon. Inclusion criteria included the following: preoperative CHF,
LVEF of 40% or less, and a QRS duration of 100 ms or greater or patients
undergoing combined mitral and aortic valve surgery. LVEF and QRS
criteria were liberalized from values of 35% and 120 ms, respectively,
in the original protocol. Exclusion criteria included the following: atrial fi-
brillation, second- or third-degree atrioventricular block, congenital heart
disease, intracardiac shunts, or heart rate of greater than 120 beats/min afterThe Journal of Thoracic and Carseparation from CPB. Preoperative data obtained by means of chart review
included the following: LVEF, as measured by means of echocardio-
graphic or left ventriculogram analysis; heart rhythm, QRS duration, and
intraventricular blocks from electrocardiographic tracings; the type of op-
eration performed; and demographic characteristics. The BiPACS trial is
ongoing, and end points will not be examined until 212 patients have
been randomized.Study Design and Optimization Protocol
Patients in the BiPACS trial are randomized to the 2 treatment groups at
the end of phase 1 (within 1 hour of the conclusion of cardiopulmonary
bypass) by using randomly permuted blocks of 4, 6, and 8 to avoid imbal-
ances that can occur with simple randomization. A treatment allocation ratio
of 1:1 was used; each group will be of equal size. The phase 1 testing de-
scribed here occurs in all patients before randomization. Optimization of
AVD, ventricular pacing site, and VVD are tested in random sequences.
Randomization and testing sequences are determined based on forms in
sealed envelopes that are not opened until needed. These forms were pre-
pared before enrollment of the first patient. Before separation from CPB,
temporary epicardial pacing leads were sewn to the right atrial (RA) ap-
pendage, anterior right ventricle (RV), and 2 randomized sites of 6 possible
sites on the LV. One of the LV leads (LV1) was placed at the basal LV at
either the obtuse margin, circumflex, or posterior regions; the second LV
lead (LV2) was placed at either the midinferomedial, midinferolateral, or
apical LV. Data from BiVP using LV1 were analyzed in this study. The
leads were attached to aMedtronic InSync III permanent biventricular pace-
maker (Medtronic, Inc, Minneapolis, Minn) mounted in an external housing
unit, and their sensing and pacing functions were tested and confirmed. An
appropriately sized electromagnetic flow probe (CarolinaMedical Electron-
ics, East Bend, NC) was placed on the ascending aorta. After separation
from CPB and establishment of stable inotrope and vasopressor dosing,
the BiVP optimization protocol was initiated. The pacing rate was set at
90 beats/min or at 10 beats/min greater than the patient’s intrinsic heart
rate if greater than 90 beats/min to ensure atrial capture up to a maximum
of 120 beats/min. These heart rates were selected empirically. A wider range
of heart rates is studied in phase 3 of the BiPACS trial, including cardiac
resynchronization therapy at the intrinsic heart rate.
Real-time aortic volume flow, echocardiograms, and arterial pressure
signals were collected with an analog-to-digital converter (PowerLab;
ADInstruments, Inc, Milford, Mass) and recorded on a personal computer
(iMac; Apple Computer, Inc, Cupertino, Calif; Figure 1). CO was measured
by integrating aortic volume flow tracings over 1 respiratory cycle with
MacLab software (ADInstruments, Inc) and custom-designed routines in
Matlab (The MathWorks, Inc, Natick, Mass).
BiVP optimization was performed by optimizing AVD, followed by
VVD. All pacing settings during optimization were conducted over 10-sec-
ond intervals and were tested twice. The use of a rapid optimization protocol
measuring changes in cardiac mechanics over brief intervals has been
described previously.14,27 AVD optimization was performed during
sequential RA BiVP, with a VVD of 0 ms. AVD was varied in 30-ms
increments, ranging from 90 to 270 ms, in randomized order. AVDs that
were longer than the patient’s intrinsic paced AVD were not tested. The
AVD yielding the highest CO was selected as the optimum AVD. AVD
optimization data from a representative patient are shown in Figure 2.
VVD optimization was then performed with the optimum AVD by varying
the VVD by 20-ms increments, ranging from80 ms (LV first) toþ80 ms
(RV first) in randomized order. CO as a function of VVD was plotted,
and the VVD yielding the highest CO was selected as the optimum VVD
(Figure 3), thereby defining the optimum BiVP parameters for the patient.
Optimized BiVP was then compared with RA pacing (AAI mode) at the
same heart rate and with NSR with no pacing, in randomized order, and
over 30-second intervals. The aortic flow probe was then removed, and
the temporary pacing leads were externalized for further BiVP optimization
in subsequent phases of the BiPACS trial.diovascular Surgery c Volume 141, Number 4 1003
FIGURE 1. Intraoperative recordings from a representative patient displaying changes in electrocardiograms (EKG), arterial pressure (AP), and aortic (Ao)
flow velocity during biventricular pacing optimization. VVD, Interventricular delay.
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For AVD and VVD optimization data and for the comparison among op-
timized BiVP, AAI, and NSR, descriptive statistics were calculated for each
group. Differences among multiple groups (3) were tested by using blocked
1-way analysis of variance. Post hoc comparisons to assess pairwise differ-
ences between groups were performed with the Tukey test adjusted for
multiple comparisons. Differences between 2 groups were tested by using
a 2-way paired Student’s t test. Statistical analysis was performed with
SAS 9.1 software (SAS Institute, Inc, Cary, NC).RESULTS
Patient flow for the BiPACS trial and this substudy covers
recruitment from April 1, 2007, to June 2, 2009. The number
of patients screened was 2261, and 60 were enrolled. Thirty-
three patients received the intended testing in phase 1 and
were subsequently randomized to BiVP (experimentalFIGURE 2. Cardiac output versus atrioventricular delay (AVD) from a rep-
resentative patient during AVD optimization.
1004 The Journal of Thoracic and Cardiovascular Surgroup) or standard of care (control group). There were no ad-
verse events during phase 1. The number of these patients
for whom the primary end point was measured was 13 in
the BiVP group and 13 in the standard-of-care group. The
study has not been completed, however, and therefore no
analysis of primary and secondary outcomes has been
done, and the present study only describes the results for
phase 1. Accordingly, the data after randomization and the
period of follow-up are not relevant and are not summarized.
Among the 33 patients who received phase 1 testing in
the BiPACS trial, 13 were eliminated from this substudy
because of frequent ventricular ectopy, an intra-aortic
balloon pump, or noisy aortic flow tracings. Ultimately, of
the 20 patients included in this substudy, there were 13
without second- or third-degree atrioventricular blockFIGURE 3. Cardiac output versus interventricular delay (VVD) from a rep-
resentative patient during VVD optimization. LV, Left ventricle; RV, right
ventricle.
gery c April 2011
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and NSR. Baseline clinical characteristics are shown in
Table E1.
The majority of patients underwent valvular surgery, in-
cluding double-valve cases, as well as combination valve
and coronary artery bypass grafting (CABG) surgery. Aver-
age age was 67  12 (standard deviation) years, and 75%
were male. LVEF averaged 33%  15%, and average
QRS duration was 116  19 ms. Nine patients underwent
combined CABG and aortic valve replacement, mitral valve
replacement, or both. Five underwent combined aortic and
mitral valve surgery, 3 underwent aortic surgery alone,
and 3 underwent isolated CABG.
Results of AVD and VVD optimization are shown in
Figure 4. The intrinsic paced AVD was greater than 150
ms in all patients and greater than 270 ms in 10 patients.
The mean optimum AVD was 171  8 versus 111  11
ms (standard error of the mean) for the mean worst AVD
(P< .001). The optimum AVD was greater than 150 ms
in 10 patients and greater than 120 ms in all but 2 patients.
Comparison of mean CO for the optimized, worst, and nom-
inal (120-ms) AVD settings showed significant differences
among groups (P< .001). In pairwise comparisons mean
CO was different in both the optimum and worst groups
compared with that at an AVD of 120 ms. BiVP with the op-
timum AVD differed from the worst AVD (P< .001), with
a mean increase in CO of 14% (range, 2%–34%). The op-
timal AVD differed from anAVD of 120ms (P<.001), with
a mean increase in CO of 7% (range, 0%–34%).
VVD optimization after AVD optimization yielded signif-
icant differences in COwhen comparing the optimum,worst,
and nominal (0-ms) VVD settings (P< .001, Figure 4). In
pairwise comparisons both the optimum and worst VVDs
differed from the nominal VVD. BiVP with the optimum
VVD differed from the worst VVD (P< .001), increasingFIGURE 4. Biventricular pacing optimization profiles for atrioventricular
delay (AVD) and interventricular delay (VVD). Mean cardiac outputs are
normalized to a scale of 100, with the worst parameter as the reference
group. Error bars depict 1 standard error of the mean.
The Journal of Thoracic and CarCO by 10% (range, 4%–29%), and from the nominal
VVD (P<.001), increasing CO by 5.0% (range, 0%–29%).
Distributions of optimal and worst AVDs and VVDs are
shown in Figures E1 and E2, respectively. An AVD of 90
ms yielded the lowest CO in the majority of patients. In all
but 2 patients, the optimal AVD was greater than 120 ms,
and in 3 patients an AVD of 120 ms was the worst setting.
VVD optimization resulted in a pattern of optimum and
worst VVD settings, ranging fromRV-first to LV-first pacing,
likely reflecting heterogeneity in the types of IVCD among
patients. In2 patients the nominalVVDyielded the lowestCO.
Comparison of optimized BiVP with AAI and NSR is
shown in Figure 5. The differences among the 3 groups
were significant (P ¼ .003), as were pairwise comparisons
between optimized BiVP versus AAI and NSR (P ¼ .003
and .019, respectively). Optimized BiVP resulted in an in-
crease in mean CO by 13% versus AAI at the same heart
rate (CO of 5.5 0.6 vs 4.9 0.6 L/min) and by 10% versus
NSR (5.0  0.5 L/min). The paced heart rate was greater in
the BiVP and AAI groups (97 3 beats/min) compared with
that seen in the NSR group (80  4 beats/min, P< .001).
DISCUSSION
Defining the best modality and method for permanent
BiVP optimization to improve BiVP response rates and
heart failure outcomes is an active area of investigation.
To our knowledge, the BiPACS trial is the first randomized
clinical trial to assess the role of temporary BiVP optimiza-
tion at multiple time points in the perioperative cardiac
surgery setting. In this substudy, which focused on intrao-
perative BiVP in the immediately post-CPB period, we
found that BiVP optimization increased CO compared
with both AAI and NSR (no pacing), with significant contri-
butions from optimization of both AVD and VVD
(Figure 4). The difference in CO between the best and worstFIGURE 5. Comparison of cardiac output with optimized biventricular
pacing (BiVP) versus right atrial pacing or sinus rhythm. Error bars depict
1 standard error of the mean. HR, Heart rate.
diovascular Surgery c Volume 141, Number 4 1005
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Msettings was considerable, ranging as high as 34% in an in-
dividual patient. Moreover, in 5 patients programming
a nominal AVD or VVD resulted in the least effective
BiVP setting, which supports a rationale for routine optimi-
zation in all patients undergoing temporary BiVP.
AVD optimization represents a balance between optimiz-
ing LV filling and atrial emptying and minimizing diastolic
mitral regurgitation. Nominal out-of-the-box AVD settings
are typically programmed to short intervals, such as 120
ms, to ensure biventricular capture. However, empiric use
of short AVDs might routinely underestimate the optimal
AVD.28 Longer intrinsic paced AVDs in the post-CPB pe-
riod allowed for testing of AVDs greater than or equal to
240 ms in the majority of patients. AVD optimization alone
resulted in a 14% increase in CO between the best and worst
settings and a 7% increase compared with an AVD of 120
ms. In all but 2 patients, the optimum AVD was longer
than 120 ms (see Figure E1). Indeed, in the immediate
post-CPB period, factors contributing to impaired diastolic
function, such as myocardial ischemia and edema, might ne-
cessitate the use of longer AVDs in patients with impaired
LV function. In this study atrio-BiVP was achieved by pac-
ing from the RA. RA pacing alters interatrial delay and the
timing of left atrial–LV contraction, which implies that the
optimum AVD would differ in right atrially paced, biatrially
paced, and atrially sensed BiVP modes.29,30
Modulation of VVD has been shown to reduce ventricular
dyssynchrony and improve hemodynamic parameters.9,10 In
the present study VVD optimization increased CO by 10%
and 5% compared with the worst and nominal settings,
respectively, underscoring the additional benefit of
VVD optimization, even after AVD has been optimized.
Whether the sequence in which AVD and VVD are
optimized affects the determination of optimized BiVP
parameters is uncertain and warrants further study.
Optimized BiVP improved CO by 13% compared with
AAI at the same heart rate, indicating that the mechanism
of hemodynamic benefit in BiVP was not explained solely
by an increased paced rate compared with the patient’s in-
trinsic sinus rate (Figure 5). This finding is consistent with
previous studies of temporary BiVP.13,17
In this study the mean preoperative LVEF (33.4%) was
higher and the mean QRS (115.7 ms) was narrower than
in permanent BiVP trials (see Table E1).2-5 Although the
criteria for permanent BiVP implantation are established,1
the predictors of acute response to temporary perioperative
BiVP have yet to be defined and are an area of ongoing in-
vestigation. Cardiac surgery and extracorporeal circulation
cause transient myocardial depression and edema and might
exacerbate conduction abnormalities. Patients with preexist-
ing LV dysfunction are among the highest-risk cardiac sur-
gery patients and are an appropriate group in which to assess
the benefit of temporary BiVP. Recent evidence suggests
that ambulatory patients with CHF and narrow QRS1006 The Journal of Thoracic and Cardiovascular Surcomplexes do not benefit from permanent BiVP, despite ex-
hibiting echocardiographic evidence of dyssynchrony.31
Whether this applies to temporary perioperative BiVP re-
mains to be seen, especially in a heterogeneous population
of ischemic and valvular cardiac surgery patients.
The mechanism by which BiVP acutely reduces dyssyn-
chrony and improves hemodynamics is not fully under-
stood, particularly in perioperative ventricular failure. We
have previously described animal models of acute right-
and left-sided heart failure and found BiVP to be beneficial
in those settings.32-34 The mechanism of action appears to
be synchronization of pressure development across the
interventricular septum, which allows the less impaired
ventricle to assist the failing one.34 These findings provide
a further rationale for studying temporary BiVP in the peri-
operative setting and will serve as a guide for future studies
examining the mechanism behind the effect demonstrated
in this study.
Another area of uncertainty lies in selecting the best met-
ric by which to assess BiVP optimization, including mea-
sures of ventricular dyssynchrony, mitral inflow, stroke
volume, and dP/dtmax. The present study optimized BiVP
based on CO, which is an important short-term end point
for end-organ perfusion, particularly in critically ill postop-
erative patients with low output states. Further study is
needed to evaluate the relationship between hemodynamic
responses to temporary BiVP, changes in ventricular syn-
chrony, and patients’ outcomes.
Outcomes data, including morbidity, mortality, intensive
care unit length of stay, and hospital costs are important
secondary objectives of the BiPACS trial. Although the ab-
solute changes in CO reported here during BiVP are rela-
tively modest, the clinical effect might be important if
amplified by a reduced requirement for b-agonists and vaso-
pressors, with secondary improvements in peripheral organ
function, fluid requirements, and incidence of arrhythmias.
Accumulating data indicate differences between patients
in the BiPACS trial and those undergoing permanent BiVP
for chronic heart failure. The optimal BiPACS trial protocol
changes over time, and the effect also changes, with benefits
being primarily rate related on postoperative day 1 but pri-
marily related to stroke volume increases in the early post-
CPB period. Absolute increases in CO during BiVP also
tend to be larger in BiPACS trial patients with higher preop-
erative ejection fractions, contradicting observations made
in patients with chronic heart failure.35 These differences
suggest that the effects of BiVP in BiPACS trial are primarily
mediated through effects on reversible myocardial injury
rather than chronic dysfunction. These differences provide
a rationale for expanding the selection of patients in our trial
beyond the current recommendations for permanent BiVP.
Digital transesophageal echocardiographic data capable of
defining changes in regional wall motion abnormalities is
an important research goal of the BiPACS trial.gery c April 2011
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Device Exemption from the Food and Drug Administration
because, as this is written, there is no biventricular pace-
maker approved for temporary pacing in the operating
room. Similarly, until our trial is completed, we will not
have definitive information regarding optimum LV lead lo-
cations. Empirically, temporary BiVP can be implemented
by adding a temporary bipolar lead configuration to the lat-
eral basal segment of the LV. These leads can be connected
to the output terminals of a standard external temporary
pacemaker in conjunction with bipolar temporary RV leads
connected to the same terminals. This will result in BIVP
with a VVD of zero. AVD can then be optimized empirically
by using mean aortic pressure or aortic flow criteria. Our cur-
rent observations indicate that the optimum AVD might be
as long as 300 ms in the early postoperative period, particu-
larly in patients with atrial latency in excess of 100 ms
(Rusanov et al, unpublished data).
In conclusion, optimization of temporary BiVP improves
CO in patients undergoing cardiac surgery with preoperative
evidence of LV systolic dysfunction and an IVCD. Individ-
ualized optimization of AVD and VVD each contributes to
the overall benefit of optimized BiVP, and optimization
should be considered a routine step in temporary BiVP
protocols. Temporary BiVP to treat low output states after
cardiac surgery is a promising area of investigation. Further
studies with larger numbers of patients will better define pa-
tient selection criteria and refine optimization techniques.
We thank the BiPACS trial patients and investigators and the
Columbia University Division of Cardiothoracic Surgery for their
participation. Lauren Bedrosian, our study coordinator 2009–
2010, and Giselle Brown provided important assistance with man-
uscript preparation.
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FIGURE E1. Distribution of optimal and worst atrioventricular delay
(AVD) settings determined during AVD optimization.
FIGURE E2. Distribution of optimal and worst interventricular delay
(VVD) settings determined during VVD optimization. LV, Left ventricle;
RV, right ventricle.
TABLE E1. Baseline characteristics
No. of patients
Total 20
Optimization analysis 20
Optimized BiVP vs AAI vs sinus rhythm 13
Age (y  SD) 67.6  12.2
Ejection fraction (%  SD) 33.4  15.4
QRS duration (ms  SD) 115.7  19.1
Male sex (%) 75
Type of operation
CABG/AVR, CABG/MVR, CABG/AVR/MVR 9
AVR/MVR 5
CABG 3
AVR 3
BiVP, Biventricular pacing; AAI, atrial pacing; SD, standard deviation; CABG, coro-
nary artery bypass grafting; AVR, aortic valve replacement;MVR, mitral valve replace-
ment or repair.
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